Fig. 6
From: Pim1 inhibition as a novel therapeutic strategy for Alzheimer’s disease
Reduced Tau pathology in 3xTg-AD Pim1i mice. a, b Representative microphotographs of CA1 hippocampal neurons from 3xTg-AD Veh and 3xTg-AD Pim1i mice stained with the anti-tau antibody CP13, which recognizes tau phosphorylated at Ser202. c Quantitative analysis of the CP13 immunoreactivity by unpaired t-test reveals that Pim1i significantly reduced tau immunoreactivity (t (9) = 2.785, p < 0.05). d Representative western blots of protein extracted from 3xTg-AD Veh, NonTg Veh, 3xTg-AD Pim1i, and NonTg Pim1i mice. Blots were probed with the indicated antibodies. The HT7 antibody recognizes total human tau and CP13 antibody recognizes tau phosphorylated at Ser202. e, f Quantitative analyses of the blots. HT7 levels were not significantly different between the two groups (t(9) = 0.558, p > 0.05). For CP13, we found a Genotype effect (t (9) = 4.563, p < 0.05), revealing higher levels of CP13 in 3xTg-AD mice. Quantitative analyses of the blots were obtained by normalizing the levels of the protein of interest to β-Actin, used as a loading control. Error bars represent mean ± SEM